Mobius Therapeutics™ To Host Livestream Discussion on July 11th
07 Jul 2022
Arsham Sheybani, MD of Washington University and Lori Pacheco of Orbis to discuss Mitosol®
12:00 noon EDT - https://www.facebook.com/ophthalmicprofessional
ST. LOUIS, July 7, 2022 /PRNewswire/ -- Mobius Therapeutics™, LLC
, a St. Louis-based perioperative ophthalmic pharmaceutical company, will host a live stream discussion between Arsham Sheybani, MD of Washington University and Lori Pacheco, RN, CRNO of Orbis International. The stream may be accessed July 11 at 12:00 noon EDT at https://www.facebook.com/ophthalmicprofessional
Preview
Source: PRNewswire
Mitosol (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use
Preview
Source: PRNewswire
Mitosol (mitomycin for solution) Kit for Ophthalmic Use (PRNewsfoto/Mobius Therapeutics, LLC)
Preview
Source: PRNewswire
Preview
Source: PRNewswire
Mobius Therapeutics™ To Host Livestream on July 11th Arsham Sheybani MD and Lori Pacheco RN to discuss Mitosol®
Tweet this
"Mitosol® customers approach intraoperative use of antimetabolites from very different, yet closely allied positions," said Ed Timm, CEO of Mobius Therapeutics. "While their needs are distinct, resolution is found with the use of Mitosol®."
Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. With room temperature storage and shelf life of up to 24 months, Mitosol® offers unique flexibility to providers, as its "shelf-ready" status permits on demand utility.
"Dr. Sheybani and Lori are renowned experts in their fields, offering impactful, real-world voices," continued Timm. "Having earned their advocacy and endorsement is a privilege. They tell us that Mitosol®, delivers value at every level: to the patient, the provider, and the American healthcare system."
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals. Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use, is the only formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline. Please see full prescribing information at https://mitosol.com/mitosol-package-insert/.
CONTACT:
Ed Timm
314-615-6932
[email protected]
SOURCE Mobius Therapeutics, LLC
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.